Maher Issa

1.3k citations

26 papers · 965 indexed · h-index 19

Impact in

Rheumatology top 2%
- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Urticaria and Related Conditions
Dermatology top 5%
- Dermatology and Skin Diseases

Papers in ⓘ

Rheumatology 16
- Rheumatoid Arthritis Research and Therapies 13
- Systemic Lupus Erythematosus Research 4
Dermatology 6
- Dermatology and Skin Diseases 6

Co-authors: Tsutomu Takeuchi (7 shared papers)Peter C. Taylor (6 shared papers)Terence Rooney (8 shared papers)Kevin Winthrop (6 shared papers)Gerd R Burmester (4 shared papers)Josef S Smolen (5 shared papers)Chadi Saifan (5 shared papers)Aleksandra Vlajnic (1 shared paper)
Journals: Journal of the American Academy of Dermatology (4 papers)Annals of the Rheumatic Diseases (4 papers)Advances in Therapy (2 papers)Arthritis & Rheumatology (2 papers)RMD Open (2 papers)
Partner nations: United States Japan Germany

In The Last Decade

Maher Issa

26 papers receiving 943 citations

Peers

Countries citing papers authored by Maher Issa

Since Specialization

Citations

This map shows the geographic impact of Maher Issa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maher Issa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maher Issa more than expected).

Fields of papers citing papers by Maher Issa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maher Issa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maher Issa. The network helps show where Maher Issa may publish in the future.

Co-authors

The 25 scholars most cited alongside Maher Issa, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Maher Issa Line = papers co-authored together Maher Issa links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 26 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis Arthritis & Rheumatology ·Peter C. Taylor, Michael E. Weinblatt, Gerd R Burmester, Terence Rooney, Sarah Witt, Chad D. Walls, Maher Issa, Claudia A. Salinas, Chadi Saifan, Xin Zhang, Anabela Cardoso, Miguel Á. González‐Gay, Tsutomu Takeuchi	2019	134
2	Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database Annals of the Rheumatic Diseases ·Peter C. Taylor, Tsutomu Takeuchi, Gerd R Burmester, Patrick Durez, Josef S Smolen, Walter Deberdt, Maher Issa, Jorge Ross Terrés, Natalia Bello, Kevin Winthrop	2021	106
3	Use of Complementary and Alternative Medicine by Patients with Cancer in Saudi Arabia The Journal of Alternative and Complementary Medicine ·Abdul Rahman Jazieh, Reem Al Sudairy, Omalkhair Abulkhair, Ahmed Alaskar, Faisal Al Safi, Nagham Sheblaq, Susan Young, Maher Issa, Hani Tamim	2012	88
4	Infections in baricitinib clinical trials for patients with active rheumatoid arthritis Annals of the Rheumatic Diseases ·Kevin Winthrop, Masayoshi Harigai, Mark C. Genovese, Stephen Lindsey, Tsutomu Takeuchi, Roy Fleischmann, John Bradley, Nicole L Byers, David L. Hyslop, Maher Issa, Atsushi Nishikawa, Terence Rooney, Sarah Witt, Christina Dickson, Josef S Smolen, Maxime Dougados	2020	66
5	Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial Current Medical Research and Opinion ·Guillermo E. Umpierrez, Maher Issa, Aleksandra Vlajnic	2006	62
6	Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis The Lancet Rheumatology ·Mark C. Genovese, Josef S Smolen, Tsutomu Takeuchi, Gerd R Burmester, Dennis Brinker, Terence Rooney, Jinglin Zhong, Daojun Mo, Chadi Saifan, Anabela Cardoso, Maher Issa, Wen‐Shuo Wu, Kevin Winthrop	2020	55
7	Triple therapy with glimepiride in patients with type 2diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: Results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study Clinical Therapeutics ·V. Roberts, John A. Stewart, Maher Issa, Barbara Lake, Robert Melis	2005	53
8	Meta-analysis of the placebo-treated groups in clinical trials of progressive MS Neurology ·Brian G. Weinshenker, Maher Issa, Jon C. Baskerville	1996	46
9	A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19 Advances in Therapy ·Thomas Bieber, Eugen Feist, Alan D. Irvine, Masayoshi Harigai, Ewa Haładyj, Susan Ball, Walter Deberdt, Maher Issa, Susanne Grond, Peter C. Taylor	2022	42
10	Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials Modern Rheumatology ·Masayoshi Harigai, Tsutomu Takeuchi, Josef S Smolen, Kevin Winthrop, Atsushi Nishikawa, Terence Rooney, Chadi Saifan, Maher Issa, Yoshitaka Isaka, Naotsugu Akashi, Taeko Ishii, Yoshiya Tanaka	2019	41
11	Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy Arthritis Research & Therapy ·Kevin Winthrop, Clifton O. Bingham, Wendy Komocsar, John Bradley, Maher Issa, Rena Klar, Cynthia E. Kartman	2019	37
12	Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials Journal of Dermatological Treatment ·Thomas Bieber, Norito Katoh, Eric L. Simpson, Marjolein de Bruin‐Weller, Diamant Thaçi, Antonio Torrelo, Angelina Sontag, Susanne Grond, Maher Issa, Xiaoyu Lu, Tracy Cardillo, Katrin Holzwarth, Jacob P. Thyssen	2022	32
13	Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials American Journal of Clinical Dermatology ·Brett King, Catherine Maari, Edward Lain, Jonathan I. Silverberg, Maher Issa, Katrin Holzwarth, Dennis Brinker, Tracy Cardillo, Fabio P. Nunes, Eric L. Simpson	2021	32
14	Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib RMD Open ·Jonathan Kay, Masayoshi Harigai, J. Rancourt, Christina Dickson, Thomas Melby, Maher Issa, Inmaculada de la Torre, Yoshitaka Isaka, Anabela Cardoso, Chadi Saifan, Edward Keystone, Ronald van Vollenhoven, Jon T. Giles, T. Huizinga, Joel M. Kremer	2020	30
15	Efficacy and Safety of Long‐Term Baricitinib With and Without Methotrexate for the Treatment of Rheumatoid Arthritis: Experience With Baricitinib Monotherapy Continuation or After Switching From Methotrexate Monotherapy or Baricitinib Plus Methotrexate Arthritis Care & Research ·Roy Fleischmann, Tsutomu Takeuchi, Michael Schiff, Douglas Schlichting, Li Xie, Maher Issa, Ivaylo Stoykov, Jeffrey Lisse, P Martínez-Osuna, Terence Rooney, Cristiano A. F. Zerbini	2019	27
16	Characterization and Changes of Lymphocyte Subsets in Baricitinib‐Treated Patients With Rheumatoid Arthritis Arthritis & Rheumatology ·Yoshiya Tanaka, Iain B. McInnes, Peter C. Taylor, Nicole L Byers, Lei Chen, Stephanie de Bono, Maher Issa, William L. Macias, Veronica Rogai, Terence Rooney, Douglas Schlichting, Steven H. Zuckerman, Paul Emery	2018	26
17	Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications Advances in Therapy ·Peter C. Taylor, Thomas Bieber, Rieke Alten, Torsten Witte, James Galloway, Walter Deberdt, Maher Issa, Ewa Haładyj, Inmaculada de la Torre, Susanne Grond, Andreas Wollenberg	2023	24
18	Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis Annals of the Rheumatic Diseases ·Yoshiya Tanaka, Bruno Fautrel, Edward Keystone, Robert Ortmann, Li Xie, Baojin Zhu, Maher Issa, Himanshu J. Patel, C. Gaich, Stephanie de Bono, Terence Rooney, Peter C. Taylor	2019	23
19	THU0078 SAFETY PROFILE OF BARICITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS UP TO 7 YEARS: AN UPDATED INTEGRATED SAFETY ANALYSIS Annals of the Rheumatic Diseases ·Mark C. Genovese, Josef S Smolen, Tsutomu Takeuchi, Gerd R Burmester, Dennis Brinker, Terence Rooney, Jinglin Zhong, Daojun Mo, Chadi Saifan, Anabela Cardoso, Maher Issa, Wen-Shuo Wu, Kevin Winthrop	2019	21
20	Pooled Analysis of Baricitinib Tolerability in Patients with Atopic Dermatitis in Relation to Acne, Headache, and Gastrointestinal Events from 8 Clinical Trials Dermatitis ·Andreas Wollenberg, Leon Kircik, Eric L. Simpson, Dennis Brinker, Norito Katoh, María José Rueda, Maher Issa, Fan Yang, Meghan Feely, Andrew Alexis	2023	5

About Maher Issa

Maher Issa is a scholar working on Rheumatology, Dermatology, Hematology, Genetics and Immunology and Allergy, having authored 26 papers that have together received 965 indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (13 papers), Dermatology and Skin Diseases (6 papers), Chronic Lymphocytic Leukemia Research (6 papers), Autoimmune and Inflammatory Disorders Research (6 papers), Systemic Lupus Erythematosus Research (4 papers), Metabolism, Diabetes, and Cancer (3 papers), Biosimilars and Bioanalytical Methods (3 papers) and Diabetes Treatment and Management (3 papers). The work is most often cited by research in Rheumatology (493 citations), Dermatology (163 citations), Hematology (182 citations), Genetics (130 citations) and Immunology and Allergy (73 citations). Maher Issa has collaborated with scholars based in United States, Japan and Germany. Frequent co-authors include Tsutomu Takeuchi, Peter C. Taylor, Terence Rooney, Kevin Winthrop, Gerd R Burmester, Josef S Smolen, Chadi Saifan, Aleksandra Vlajnic, Guillermo E. Umpierrez and Anabela Cardoso. Their work appears in journals such as Journal of the American Academy of Dermatology, Annals of the Rheumatic Diseases, Advances in Therapy, Arthritis & Rheumatology and RMD Open.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact